Postmarketing Safety Reporting Requirements for Drug and Biologic Products

This website serves as a resource to applicants, licensed manufacturers, packers, distributors and responsible persons subject to FDA’s requirements for postmarketing safety reporting for human drugs and biological products under 21 CFR §§ 310.305, 314.80, 314.98, 600.80, 1271.350 and Section 760 of the Food Drug and Cosmetic Act (FDCA). 

Regulations and Laws 

 Regulation or Law Product
 21 CFR § 310.305

Prescription drugs marketed for human use without approved new
drug applications

 21 CFR § 314.80Drugs with approved new drug applications (NDAs)
 21 CFR § 314.98Drugs with approved abbreviated new drug applications (ANDAs)
 21 CFR § 600.80

Biologics with approved biologics license applications (BLAs)

 21 CFR § 1271.350Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
 Section 760 of the FDCA

Nonprescription human drug products marketed without an
approved application



Proposed Rules

Other Resources


Page Last Updated: 02/13/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English